



Drug Discovery 2018

Halls N4 & N5: ExCeL, London

Entrance: N2

9th – 10th October 2018



Drug Discovery 2018 Platinum Sponsor



www.elrig.org

Welcome To Drug Discovery 2018

As Scientific Program chairs it is our great pleasure to welcome you to London and the 12th Annual ELRIG Drug Discovery event.

Through the efforts of our volunteer organising committee, we have been able to assemble a world-class line up of scientific speakers organised into 8 thematic tracks over 2 days. Some, like our Innovations in Biochemical and Biophysical Hit-finding Techniques, and Chemistry Innovations sessions will be recognisable from previous years. Others, such as our Data Sciences and AI, and our Antibodies and Novel Large Molecule Platforms, tracks are new and reflect hot topics and trends in the Drug Discovery Field. We are also delighted to welcome a session hosted by the BPS, focusing on the search for more effective analgesics. With 2 exciting plenary lectures, over 50 session speakers, 180 posters and a vibrant exhibition hall we are sure there will be something for all!

This year's venue, the London Excel Arena is a fantastic place for us to convene. The state of the art conference facilities positioned close to London's vibrant city centre provide a perfect backdrop for the scientific and networking

interactions upon which ELRIG is founded. The excellent travel links to London will hopefully see you arrive fresh and energised!

We would like to thank Rhona Bennett, Clare Cockerham and Tara Shanks for their fantastic contribution in shepherding ourselves and the Program Chairs through the organising process. Without their help, together with the ELRIG back office and volunteers, this meeting would not be possible.

Without you, the meeting delegate, we have nothing too. We thank you in advance for your participation and look forward to connecting with you over the next couple of days. As always, we welcome your feedback on how we can further improve the agenda to ensure the growth and success of ELRIG Drug Discovery for the future. Have fun in London and enjoy the opportunity to discuss emerging Science within a vibrant and collegiate environment!



Rachel Grimley
(AstraZeneca)



Tim Hammonds
(Cancer Research)



Katy Kettleborough
(LifeArc)

A Message from the Chair of ELRIG, Steve Rees



On behalf of ELRIG I would like to welcome you to the 12th Drug Discovery meeting held for the first time in London. We anticipate over 1400 attendees making this the largest drug discovery scientific congress held in Europe in 2018. The last year has seen a significant growth in ELRIG. We have hosted five successful scientific meetings, our networking events programme continues to grow with locations added in Oxford and London, and we have launched the Early Career Professional Workgroup, with several

events planned at this meeting. We have an exciting scientific program in place for 2019, including our first meeting on the use of CRISPR in drug discovery to be held in Oxford in February. This meeting will explore how CRISPR is enabling target identification, target validation, and the creation of cellular and animal models of disease. Looking ahead to the next two days I would like to thank the programme committee, session chairs, speakers, exhibitors and of course you for attending this meeting, and to learn more about ELRIG please follow us on Linked-in or Twitter.

Drug Discovery 2018 Session Chairs

Chemistry Innovations



Nicole Hamblin
(Charles River)



Martin Swarbrick
(CRUK TDL)

Innovations in Biochemical and Biophysical Hit Finding Techniques



Geoff Holdgate
(AstraZeneca)



Andrew Scott
(Concept Life Sciences)

Innovations in Cellular HTS and Compound Profiling



Eddy Stevens
(Ario Pharma)



Mark Slack
(Evotec)



David Matthews
(LifeArc)



Andy Popplewell
(UCB)

Anti-Infectives and Rare Diseases



David Brown
(Healx Ltd)



Chris Dowson
(Warwick University)



Andy Pearce
(GlaxoSmithKline)



Julie Frearson
(CRL)

The Opioid Crisis, Addiction and the Search for More Effective Analgesics



Sarah Nickolls
(GlaxoSmithKline)



David Kendall
(Pharmnovo)

Data Sciences and Artificial intelligence



John Overington
(MDC)



Bissan Al-Lazikani
(Institute of Cancer Research)

Plenary Keynote Speakers



Professor Janet Thornton
(European Bioinformatics Institute)

"Drug repurposing for ageing research"
Tuesday 9th October 2018: 09:15: Platinum Suite 1

Many increasingly prevalent diseases share a common risk factor: age. However, relatively little is known about pharmaceutical interventions against ageing, despite our knowledge that many genes and pathways are important in the ageing process and numerous studies demonstrate that genetic interventions can lead to a healthier ageing phenotype. An important challenge is to assess the potential to repurpose existing drugs for initial testing on model organisms, where such experiments are possible. To this end, we present several approaches to rank drug-

like compounds according to their likelihood to modulate ageing or their testability in model organisms. We consider information on genetic effects on ageing, orthology relationships and sequence conservation, 3D protein structures and expression data, combined with data for given drug molecules. The top ranked compounds are thus prime candidates for *in vivo* testing of their effects on lifespan in model organisms or cells. As such, these compounds are promising as research tools and ultimately a step towards identifying drugs for a healthier human ageing.



Dr. Jonathan Milner
(Meltwind)

"Opportunities in the Golden Age of Biology"
Wednesday 10th October 2018: 09:10: Platinum Suite 1

We live in a Golden Age of Biology. Discoveries in the last fifty years mean we now have unprecedented power to diagnose, prevent and treat disease. From "Omics" through stem cells to Artificial Intelligence, the pace of scientific data and discovery is accelerating exponentially.

How do we translate this golden age into world leading life science companies that will have a huge positive impact on human health? Here Jonathan will discuss exciting areas of biology and the opportunities they present for life-science entrepreneurs.

Information for Participants

Registration

Registration will take place on the ground floor. Please collect your name badge and your delegate bag from the registration desk. For security reasons it is essential to wear your badge at all times whilst attending Drug Discovery 2018.

Attendees will not be allowed access to any lecture theatre or the exhibition area without a name badge. The registration desk will open during the following times:

Tuesday 9th October: 08:00–15:30

Wednesday 10th October: 08:00–15:30

WI-FI at Drug Discovery 2018

WI-FI at ExCeL, London is free. Select the network **ExCel Free Wi-Fi** to be connected. There is no password.

ELRIG Mobile App

Download the free ELRIG app and access all our conference information, programme and more from your phone or tablet.

- View the event programme, presentation and poster abstracts and speaker profiles
- View the exhibitor guide
- View the delegate and exhibitor list
- Organise your day with your own favourites list
- Share your profile as vCard and QR Code and scan exhibitor QR code information tags.
- Network – contact delegates, other exhibitors and speakers easily through opt-in directories and integration with LinkedIn, Twitter and Facebook
- Vote for your favourite technology and poster



To download the ELRIG app, visit the app store appropriate to your tablet or smart phone, scan the QR code or visit the ELRIG website:

www.elrig.org/mobile-app/

Technology Prizes


Please have a good look around the exhibition. Our exhibitors support keeps ELRIG events free to attend. We invite all delegates to vote for what you think is the best technology being shown in the exhibition using the ELRIG App.

Poster Competition

Every year at ELRIG Drug Discovery we get a fantastic range of Posters presented. Use the ELRIG App to vote for what you think is the best poster.

Vote for your Favourite!

Voting for your favourite technology and poster couldn't be simpler! When you have downloaded the ELRIG App, click on the vote for favourites icon on the Drug Discovery 2018 Overview page




and complete the online form.

Both the poster and technology winners will be announced in the closing address in Platinum Suite 1 - 16:15 on Wednesday 10th October). Votes cast by 3pm on Wednesday 10th will be entered into a PRIZE DRAW to win an Amazon Echo Dot.*



*To be eligible to win either of the prize draw you must be at the conference closing remarks in person.

ExCeL, London Floorplan




Exhibitor Booth Locations

Admescope Ltd	A4	Eurofins Pharma Discovery Services	B3	Pelago Bioscience AB	R2
Agilent Technologies	R4	European Collection of Authenticated		PerkinElmer	B2
Andrew Alliance	E13	Cell Cultures	C5	Phasefocus	I28
Apollo Scientific	A14	Formulatrix, Inc.	B1	Porvair Sciences Ltd	R5
Aptamer Group Limited	E9	Fritz Gyger AG	C7	Promega UK Ltd	E5
Aurelia Bioscience	F7	FUJIFILM Cellular Dynamics	A9	Proteintech Europe	L5
Axon Biosystems	IZ2	GEN	MP7	Proteome Sciences Plc	E14
Beckman Coulter GmbH	C0, C1, C10, C11	Genedata AG	B16	Reaction Biology Corporation	E8
Bigneat	E3	Greiner Bio One	A6	ReprotoCELL	A10
BioAscent Discovery Ltd	E15	Hamilton Sales and		RxNet	A16
BioIYT	A5	Service UK LTD	D0, D1, D10, D11	Sarstedt Ltd	E0
BioNavis Ltd	E12	Horizon Discovery	L8	Sartorius Stedim Biotech	L1, L2, L3, L4
Bio-Rad	D9	I&L Biosystems UK Ltd	B15	SB Drug Discovery	B6
Biosero Inc	A11	Idea Bio-Medical Ltd	D3	ScreenIn3D	I210
BioStrata Ltd	L7	INTEGRA Bioscience Ltd	E6, E11	Select Science	MP1
BioSystems Technology	IZ1	KBiosystems	B4, B5	STEMCELL Technologies	A15
BioTek Instruments Ltd	F5	Labcyte Inc.	C3, C8	Syngniture Discovery	E2
BlueCatBio GmbH	C6	LabLogic Systems Limited	A1	Synthego	D6, D7
BMG LABTECH Ltd	B12, B13	Langton Howarth	Careers Zone	Taconic	F6
British Pharmacological Society	L6	LGC - ATCC	B14	Takara Bio Europe	R1
Brooks Life Science	C9	Life Science Methods B.V.	I26	Tecan UK Ltd	A2, A3
Cambridge Bioscience	E1	LifeArc	B8, B9	Technology Networks	E10
Cambridge Research Biochemicals	R6	Malvern Panalytical Ltd	R3	Thermo Fisher Scientific	B10
Cancer Research	A12	Medicines Discovery Catapult	D2	Tissue Solutions	C4
Cell Guidance Systems	IZ7	Merck	R7, R8	Titian Software Ltd	B11
Charles River	F4	Metron Biosciences Limited	B7	UK Pharmacogenetics & Stratified	MP6
Cisbio	E7	MicroMatrices Associates Ltd	IZ4	Medicine Network	D8
Collaborative Drug Discovery	E4	Miltenyi Biotec Ltd	A7, A13	UPM-Kymmene Corporation	E16
CytoSMART Technologies BV	A8	MIP Diagnostics Limited	D4	Wagner Medizin- und Pharmatechnik	I25
Drug Discovery News	MP4	Molecular Devices (UK) Ltd	B0	GmbH & Co. KG	A18
Drug Discovery World	MP3	Newcells Biotech	I29	Xpert Automation	MP3
Drug Target Review	MP2	NMI TT Pharmaservices	C2	Ziath	
Ectica Technologies AG	IZ3	Peak Analysis Automation Ltd	F3	Zyme Communications	
ELRIG	A0	Peak Proteins Ltd	D5		

Drug Discovery 2018 - Exhibition Hall Floorplan

ExCeL Exhibition Halls N4 & N5



What's New at Drug Discovery 2018



Learning Paths:

New to Drug Discovery 2018 are our Learning Paths; Follow our suggested agendas through the meeting to learn as much as possible about the hottest topics in Drug Discovery!

Training in Breakthrough Scientific Techniques:

Free to attend training course on the latest, breakthrough scientific techniques

Innovation Zone:

ELRIG supports fledgling biotech companies, who will be exhibiting their latest technologies in the Innovation Zone

Workshops:

Free to attend workshops on practical aspects of ground breaking technologies and techniques

Chairman's Reception:

The Drug Discovery networking event of the year, where senior leaders meet in an informal gathering - by invitation only!

Early Career Professional Development:

For those starting their careers in drug discovery, networking sessions, panel discussion and Workshop.

Networking:

Meet up 1200 fellow Drug Discovery practitioners at our network event

CRO Village:

Find the contract research organisation, that meets your need in their dedicated exhibition village

Early Career Professional

Careers in Drug Discovery: Where to next?

Tuesday 9th October 14:00 - 15:00
Platinum Suite 6

Are you a post-doc, postgraduate, early career researcher or professional (ECP) scientist looking to start or build your career in drug discovery? If so, understanding the wide array of opportunities and career paths for you beyond academia, and how to make that step, is critical to your success.

We invite you join us at our ECP panel discussion event at ELRIG DD 2018, Europe's largest free to attend Drug Discovery conference.

- Hear panellists discuss and share their experiences and personal stories in making this transition
- Increase awareness of different roles and career paths in the drug discovery industrial community
- Learn more about career and professional development support available to you
- Meet other ECP scientists & expand your network
- Prepare for the next exciting step in your career!

Facilitator:

Dr Clare Viney
(CEO, CRAC Vitae)

Panellists:

Dr David Brierley
(Cell Biology Team Leader, GlaxoSmithKline)

Dr Andrew Whale
(Senior Scientist/Manager, ImmunoCore)

Supa Begum
(Technical Sales Consultant, Miltenyi Biotech)

Dr Clare Russell (MD Biostrata)

Careers in Drug Discovery: Network like a boss

Tuesday 9th October 17:15 - 18:15
Career Zone

Are you a post-doc, postgraduate, early career researcher or professional (ECP) scientist looking to start or build your career in drug discovery? If so, building and managing your network of contacts is critical to your success.

We invite you join us at our ECP speed networking event at ELRIG DD 2018, Europe's largest free to attend Drug Discovery conference

- Speed meet 1:1 with selected representatives across the drug discovery community, including pharma, biotech, CROs, non-for profit and more

- Learn how to network effectively
- Increase your awareness of roles and career paths in industry, academia and beyond
- Expand your list of contacts and potential future employers
- Open new doors to an exciting future

Careers in Drug Discovery: Preparing for your new role

Wednesday 10th October 14:00 - 15:00
Platinum Suite 6

Are you a post-doc, postgraduate, early career researcher or professional (ECP) scientist looking to start or build your career in drug discovery? If so, understanding how best to prepare for your next step, and maximize your chance of success is critical.

We invite you join us at our ECP workshop event at ELRIG DD 2018, Europe's largest free to attend Drug Discovery conference:

- Learn from employer internal recruiters, recruitment consultants and industry hiring managers as to what really differentiates you in the application process
- Get practical advice on preparing your 'industry appropriate' CV and interview technique
- Meet other ECP scientists & expand your network
- Prepare for the next exciting step in your career!

Chair: Emma Howarth (MD. Langton Howarth)

Presenters:

Jo Raper (HR Adviser, Lhasa)
Sue Ward (Talent Acquisition, Illumina)

Drug Discovery 2018 Learning Paths: Your Learning Experience Starts Here

As an Early Career Professional, with 50 free-to-attend talks, workshops and technical training sessions, Drug Discovery 2018 is THE place to learn about some of the hottest topics in life science research. Choose from the five learning paths we have created, to follow your area of research and plan your Drug Discovery experience:

- Non-small molecule drug discovery
- How working with CRO's can help you discover drugs
- Innovative technologies and techniques
- How collaborative working is tackling challenging diseases
- Novel targets and molecules

Your Drug Discovery 2018 Learning Experience Starts Here

As an Early Career Professional, with 50 free to attend talks, workshops and technical trainings, Drug Discovery 2018 is the place to learn about your topic of interest in life science research. Choose from the learning paths below, to follow your area of research and plan your Drug Discovery experience.

Non-Small Molecule Drug Discovery	How Working With CRO's Can Help You Discover Drugs	Innovative Technologies And Techniques	How Collaborative Working Is Tackling Challenging Diseases	Novel Targets And Molecules
Platinum Suite 1: 9 Oct 11:00	Platinum Suite 1: 9 Oct 16:00	Platinum Suite 2: 9 Oct 11:45	Platinum Suite 3: 9 Oct 11:00	Platinum Suite 4: 9 Oct 11:30
<i>Highly potent and selective tumour targeting bicyclic peptides - a novel approach to cancer therapy</i> Gemma Mudd (Bicycle Therapeutics)	<i>Capture Compound® Mass Spectrometry: On- and Off-Target Deconvolution</i> Andrew Cridland (Charles River)	<i>Cellular thermal shift assays in high throughput: a 1536-well cellular target engagement assay for drug discovery</i> Lorena Kallal (GlaxoSmithKline)	<i>Using AI to accelerate combinations drug discovery for rare diseases</i> Michale Bouskila-Chubb (Healx Ltd)	<i>Neuro-immune interactions and novel targets for chronic pain</i> Marzia Malcangio (Kings College London)
<i>How the chemical design and synthesis of linkers used in antibody drug conjugates drives the success of ADC drug development.</i> Mark Frigerio (Abzena)	<i>The Centaur Chemist: AI in drug design</i> Andrew Hopkins (ExScientia)	<i>Organoids: Predicting clinical responses in an in vitro model</i> Robert Vries (Hubrecht Organoid technology)	<i>The Dementia Discovery Fund – a novel, collaborative venture</i> Laurence Barker (Dementia Discovery Fund)	<i>Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of haematological malignancies.</i> Bernard Barlaam (AstraZeneca)
Platinum Suite 2: 10 Oct: 11:30	Platinum Suite 3: 10 Oct: 14:30	Platinum Suite 1: 9 Oct: 16:30	Platinum Suite 3: 10 Oct: 15:45	Platinum Suite 3: 9 Oct: 14:00
<i>Patient-Focused Bispecific Target Discovery by High Throughput Functional Screening</i> Ahmad Kamal (UCB Celltech)	<i>Building bridges: An academic-industry exercise</i> Mark Slack (Evotec)	<i>Using PROTACs as probes to study intracellular target engagement against proteins with unknown function</i> Matthew Cheeseman (Institute of Cancer Research)	<i>Apollo Therapeutics - a novel, collaborative drug discovery model</i> Richard Butt (Apollo Therapeutics)	<i>An academic entrepreneur's thoughts about drug discovery where reductionism bumps up against biological complexity and drug promiscuity: generating meaningful targets</i> Steven Zimmer (MitoDys Therapeutics)
Platinum Suite 1: 10 Oct: 14:00	Platinum Suite 1: 10 Oct: 15:15	Platinum Suite 1: 10 Oct: 11:30		Platinum Suite 4: 9 Oct: 14:30
<i>Biophysical and Biochemical assay technologies for antibody discovery, and considerations for their uses.</i> Martin Redhead (UCB)	<i>Smarter IDO inhibitor profiling by incorporating biophysical, biochemical and cellular target engagement approaches</i> Scott Pollack (Signature Discovery)	<i>Application of Acoustic Mist Ionization Mass Spectrometry (AMI-MS) for the Development of Kinase Assays</i> Deepika Srivastava (AstraZeneca)		<i>Natural and engineered genetics for new pain target discovery</i> Alex Gutteridge (GlaxoSmithKline)
Platinum Suite 2: 10 Oct: 15:15		Platinum Suite 2: 10 Oct: 14:30		Platinum Suite 3: 9 Oct: 16:30
<i>Targeting Solid Tumours with Antibody Fragment Drug Conjugates</i> Bryan Edwards (Antikor Biopharma)		<i>Single domain antibody platform for delivery of biologics across the blood brain barrier</i> Pawel Stocki (Ossianix Inc)		<i>Combination drugs for safe treatment of children with rare cancers</i> David Brown (Healx Ltd)
		Platinum Suite 4: 10 Oct: 15:15		Platinum Suite 2: 10 Oct: 15:45
		<i>Artificial Intelligence in Drug Discovery from a Medicinal Chemistry Viewpoint</i> Ola Engkvist (AstraZeneca)		<i>The Discovery of Anti-BCMA: One Antibody, Two Flavours</i> Stephen Ashman (GlaxoSmithKline)

Drug Discovery 2018 at a Glance: Tuesday 9 October 2018



Platinum Suite 1:	Platinum Suite 2:	Platinum Suite 3:	Platinum Suite 4:
Chemistry Innovations	Innovations in cellular HTS and compound profiling	Anti-infectives & Rare Diseases	The opioid crisis, addiction and the search for more effective analgesics
09:15 - 10:15 - Plenary Keynote - Platinum Suite 1: Professor Janet Thornton (European Bioinformatics Institute) <i>Drug re-purposing for ageing research</i>			
11:00 - 11.30	11:00 - 11.30	11:00 - 11.30	11:00 - 11.30
Highly potent and selective tumour targeting bicyclic peptides - a novel approach to cancer therapy Gemma Mudd (Bicycle Therapeutics)	Using Single Cell Sequencing for Drug discovery Martin Guiliams (VIB institute for inflammation)	Using AI to accelerate combinations drug discovery for rare diseases Michale Bouskila-Chubb (Healx Ltd)	Ligand bias at opioid receptors - what is it good for? Professor Eamonn Kelly (University of Bristol)
11:45 - 12.15	11:45 - 12.15	11:45 - 12.15	11:30 - 12.00
How the chemical design and synthesis of linkers used in antibody drug conjugates drives the success of ADC drug development. Mark Frigerio (Abzena)	Cellular thermal shift assays in high throughput: a 1536-well cellular target engagement assay for drug discovery Lorena Kallal (GlaxoSmithKline)	Economic models to incentivise antibacterial drug R&D Ursula Theuretzbacher (Center for Anti-Infective Agents)	Neuro-immune interactions and novel targets for chronic pain Marzia Malcangio (Kings College London)
14:00 - 14.30	14:00 - 14.30	14:00 - 14.30	12:00 - 12.30
Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of haematological malignancies. Bernard Barlaam (AstraZeneca)	Efficiently identifying and characterizing HTS hits with imaging biosignatures Steffen Jaensch (Janssen Pharmaceutica)	An academic entrepreneur's thoughts about drug discovery where reductionism bumps up against biological complexity and drug promiscuity: generating meaningful targets Steven Zimmer (MitoDys Therapeutics)	Targeting the reward system in addiction – structure-based drug design of selective orexin 1 receptor antagonist Kirstie Bennett (Heptares Therapeutics)
14:45 - 15:15	14:45 - 15:15	14:45 - 15:15	14:00 - 14:30
Biocatalysis in drug discovery Doru Roiban (GlaxoSmithKline)	Implementation of a patient derived disease model using human iPSC for drug screening Magda Bictash (ARUK)	The case for combination antimicrobial chemotherapy for AMR William Hope (University of Liverpool)	Current progress and future opportunities in the development of Nav1.7 blockers for the treatment of pain Zahid Ali (Mundipharma)
16:00 - 16:30	16:00 - 16:30	16:00 - 16:30	14:30 - 15:00
Capture Compound® Mass Spectrometry: On- and Off-Target Deconvolution Andrew Cridland (Charles River)	Organoids: Predicting clinical responses in an <i>in vitro</i> model Robert Vries (Hubrecht Organoid technology)	Multi-targeting to reduce bacteria resistance Chris Dowson (University of Warwick)	Natural and engineered genetics for new pain target discovery Alex Gutteridge (GlaxoSmithKline)
16:30 - 17:00	16:30 - 17:00	16:30 - 17:00	15:00 - 15:30
Using PROTACs as probes to study intracellular target engagement against proteins with unknown function Matthew Cheeseman (Institute of Cancer Research)	Biomicrofabrication of Cellular Interfaces and Models Cristina Bertulli (Cambridge University)	Combination drugs for safe treatment of children with rare cancers David Brown (Healx Ltd)	Mechanisms based approaches to novel analgesic development: what are the alternatives to opioids for chronic pain? Vicky Chapman (University of Nottingham)
16:00 - 16:30			
<i>Delta opioid receptor agonists; potential in chronic pain therapy</i>			
<i>Delta opioid receptor agonists; potential in chronic pain therapy</i>			
David Kendall (PharmNovo AB/UK)			
16:30 - 17:00			
<i>Altered pain processing in a rat model of negative affective state: a role for the endogenous cannabinoid and opioid systems</i>			
Dave Finn (NUI Galway)			

Drug Discovery 2018 at a Glance: Wednesday 10 October 2018

Platinum Suite 1:	Platinum Suite 2:	Platinum Suite 3:	Platinum Suite 4:
Innovations in biochemical and biophysical hit finding techniques	Antibodies and Novel Large Molecule Platforms	Drug Discovery Networks - Alliances, Partnerships, CRO Relationships and Open Innovation	Data Sciences and Artificial Intelligence
09:10 - 10:10 - Plenary Keynote - Platinum Suite 1: Dr Jonathan Milner (Meltwind) Opportunities in the Golden Age of Biology			
10:50 - 11:20	10:50 - 11:20	10:50 - 11:20	10:50 - 11:20
Crude reaction screening: KA/D, kd, structure and more. James Murray (Vernalis R&D Ltd)	Assessing and Addressing Biopharmaceutical Aggregation David Brockwell (Astbury Centre, University of Leeds)	A business model for open drug discovery Aled Edwards (M4K Pharma)	Computer-Aided Synthesis Planning Marwin Segler (Benevolent AI)
11:30 - 12:00	11:30 - 12:00	11:30 - 12:00	11:30 - 12:00
Application of Acoustic Mist Ionization Mass Spectrometry (AMI-MS) for the Development of Kinase Assays Deepika Srivastava (AstraZeneca)	Patient-Focused Bispecific Target Discovery by High Throughput Functional Screening Ahmad Kamal (UCB Celltech)	Medicines Discovery Catapult: a new model for collaborative R&D Graeme Wilkinson (Medicines Discovery Catapult)	The Centaur Chemist: AI in drug design Andrew Hopkins (ExScientia)
14:00 - 14:30	14:00 - 14:30	14:00 - 14:30	14:00 - 14:30
Biophysical and Biochemical assay technologies for antibody discovery, and considerations for their uses. Martin Redhead (UCB)	Structurally mapping next-generation sequencing repertoires of antibodies to aid in-silico therapeutic design Charlotte Deane (University of Oxford)	The Dementia Discovery Fund – a novel, collaborative venture Laurence Barker (Dementia Discovery Fund)	Integrative Big Data for Cancer Therapy and Drug Discovery Bissan Al-Lazikani (Institute of Cancer Research)
14:30 - 15:00	14:30 - 15:00	14:30 - 15:00	14:30 - 15:00
Immunoassays for Drug Discovery: Balancing complex cellular systems with high throughput screening. Steve Anderton (Aquila Biomedical)	Single domain antibody platform for delivery of biologics across the blood brain barrier Pawel Stocki (Ossianix Inc)	Building bridges: An academic-industry exercise Mark Slack (Evotec)	Next-Generation Drug Discovery: Quantum Physics Meets Machine Learning Graham Simpson (GTN)
15:15 - 15:45	15:15 - 15:45	15:15 - 15:45	15:15 - 15:45
Smarter IDO inhibitor profiling by incorporating biophysical, biochemical and cellular target engagement approaches Scott Pollack (Signature Discovery)	Targeting Solid Tumours with Antibody Fragment Drug Conjugates Bryan Edwards (Antikor Biopharma)	Discovery Partnerships with Academia, integrated collaborations leading towards innovative medicines Duncan Holmes (GlaxoSmithKline)	Artificial Intelligence in Drug Discovery from a Medicinal Chemistry Viewpoint Ola Engkvist (AstraZeneca)
15:45 - 16:15	15:45 - 16:15	15:45 - 16:15	15:45 - 16:15
Fluorescence assay technologies for hit discovery Helena Lindmark (AstraZeneca)	The Discovery of Anti-BCMA: One Antibody, Two Flavours Stephen Ashman (GlaxoSmithKline)	Apollo Therapeutics - a novel, collaborative drug discovery model Richard Butt (Apollo Therapeutics)	Learning the biology of chemistry Matt Tudor (Merck)

Workshops at Drug Discovery 2018



Sartorius Stedim Biotech: Live-cell analysis techniques: developing translational assays for drug discovery

Tuesday 9th October: Platinum Suite 6
10:50 - 12:15

Translational assays provide critical bridges between in vitro models and the clinic, enabling a greater understanding of disease and potential therapy. To meet these requirements has resulted in an increased employment of more complex and advanced cell models, including co-culture systems, primary/iPSC-derived cells and patient specific tissue organoids. This raises the bar for assay development and functional profiling methods that are able to extract the deeper content provided by these models, whilst maintaining throughput and ease of use.

In this workshop, we will discuss the latest developments in live-cell analysis. Through BioTech and CRO end-user case study presentations, new applications in therapeutic discovery projects will be reviewed. These include immune cell killing assays in 2D & 3D, phagocytosis, antibody internalization measurements and tumour-spheroid analyses. Interactive discussions will be encouraged to explore how live-cell analysis is best aligned with discovery project requirements and how they can be further developed to address unmet need.

The workshop is targeted toward researchers with general interest in translational cell models, cell-based assays, cancer biology and immunology, including current and prospective users.

Agenda

- 10:50 – 10:55 Welcome & introductions
Tim Dale (Sartorius)
- 10:55 – 11:20 Kinetic measurements of immune cell cytotoxicity
Dan Foxler (GammaDelta Therapeutics)
- 11:20 – 11:45 Live cell imaging assays for Immuno-oncology drug screening
Jessy Cartier (Aquila BioMedical)
- 11:45 – 12:10 New IncuCyte applications: Multi-spheroids and Cell-by-Cell analysis
Tim Dale (Sartorius)
- 12:10 – 12:15 Concluding remarks



Peak Analysis and Automation Ltd: Harmony, Overlord and the S-LAB automated plate handler - a powerful combination.

Tuesday 9th October: Platinum Suite 5
11:30 - 12:30

Harmony™ is an easy to use, configurable user interface that allows the control of a small or large system. S-LAB™ is a small footprint, reliable plate handler that supplies microplates from a stack, rack, hotel or incubator. Overlord™ allows control of over 300 instruments with the ability to delid, regrip and process barcodes. PAA have combined these technologies to provide the perfect solution to low cost automation of most instruments. Come to the Overlord User Group meeting at ELRIG Drug Discovery 2018 to discover how S-LAB can automate your lab quickly and cost effectively.



Titian Software & Tecan: Are We Nearly There Yet? Past Present and Future of Sample Management

Tuesday 9th October: Platinum Suite 7
13:15 - 14:15

Tecan and Titian will be presenting their long standing partnership in software integration combining sample management and laboratory automation. This builds on the historical work to allow Mosaic users to be guided through setting up a run on a Tecan liquid handler. The topics will range from the humble beginnings of the Genesis integration with Mosaic – to the new Fluent® and FluentControl™ updates which enable the combined software to deliver high capacity and outstanding speed. The platform provides excellent precision, throughput and walk-away time with live inventory updates. Also to be discussed will future directions to further enable both companies to make it easy to get more done, more confidently and hence support scientists in delivering life-changing research.

Speakers

- Kevin Moore** (Head of Markets & Applications, Tecan)
- Toby Winchester** (Automation Product Manager, Business Application Consultant Team Leader, Titian)
- Jason Meredith** (Head of Software Product Management, Tecan)



SiLa Workshop: Closing the loop in the Lab using Artificial Intelligence

Tuesday 9th October: Platinum Suite 5

14:00 – 17:30

Artificial Intelligence (AI) tools are starting to become established in pharmaceutical research and life sciences more generally - with some 69% of companies in the sector using AI and related techniques. Typical uses include mining images and other large data sets for new insights. The possibility is now emerging to use AI to help plan the next experiment – ‘to close the loop’ – for faster and better results. This workshop brings together experts in the lab, and AI to look at closing the loop with AI for two applications: Screening and Chemical synthesis. We will aim to address the following questions: What is possible now? What have the experiences been? What are the pitfalls? And finally, (and perhaps most important!) how can I benefit?

Join us for an interactive workshop session, led by industry experts, where we will present use cases and overviews from a range of Scientists. There will be plenty of time for questions and debate as well as presentations on innovative developments in the field.

Agenda

Medicinal Chemistry/new small Molecules

- 14:00 – 14:10 Introduction and scene setting
Patrick Courtney (Director, SiLA)
- 14:10 – 14:30 Activity-directed synthesis: a platform for bioactive molecular discovery
Adam Nelson (Rosalind Franklin Institute/Leeds University)
- 14:30 – 14:50 Accelerating drug discovery through automation
Garry Paireaudieu (AstraZeneca)
- 14:50 – 15:10 ROAR: The Centre for Rapid Online Analysis of Reactions
Mimi Hii (Imperial College/ROAR)
- 15:10 – 15:30 Discussion
- 15:30 - 16:00 COFFEE

Screening

- 16:00 – 16:20 Smarter screening, how to leverage AI to ‘close the loop’
Kevin Teburi (Genedata)
- 16:20 – 16:40 Lundbeck’s transition to integrated drug discovery informatics platform
Plamen Petrov (Lundbeck Pharma)

- 16:40 – 17:00 Adalab closed loop and underpinning ontologies
Larisa Soldatova (Goldsmiths College/ ADALab)
- 17:00 – 17:30 Enabling ML and AI through a Standards-based Data Pipeline
Burkhard Schaefer, (BSSN Software / SiLA Board of Directors)
- 17:30 End of workshop



CamBioscience Training Zone:

Cerebral Organoids

Tuesday 9th October: 08:20 - 12:30

- 08:20-8:45 CamBioScience hands-on training courses overview
- 08:45-10:15 Meet the CamBioScience team to discuss hands-on and digital training courses to enhance your technical skills and advance your career.
- 10:15-10:50 How to create and take personalised training courses online thanks to Artificial Intelligence
- 10:50-12:30 Digital lecture “Cerebral Organoids” on our AI-Learning platform OBRIZUM® by world leading expert in the field
Dr Madeline Lancaster (University of Cambridge)
- “Check your knowledge” interactive session!

CRISPR Design & Strategy

Tuesday 9th October: 12:30 - 14:00

- 12:30-14:00 CamBioScience hands-on training courses overview
- How to create and take personalised training courses online thanks to Artificial Intelligence
- 14:00-15:30 Digital lecture on “CRISPR Design & Strategy” on our AI-Learning platform OBRIZUM with **Dr Oliver Baker** (King’s College London) and **Dr Ben Davies** (University of Oxford)
- “Check your knowledge” interactive session!
- 15:30-16:00 How to create and take personalised training courses online thanks to Artificial Intelligence

Cerebral Organoids

Tuesday 9th October: 16:00 - 18:45

- 16:00-17:00 Digital lecture “Cerebral Organoids” on our AI-Learning platform OBRIZUM® by world leading expert in the field
Dr Madeline Lancaster (University of Cambridge)
“Check your knowledge” interactive session!
- 17:00-18:45 Meet the CamBioScience team to discuss hands-on and digital training courses to enhance your technical skills and advance your career.

CRISPR Design & Strategy

Tuesday 9th October: 08:00 - 12:30

- 08:00-9:00 CamBioScience hands-on training courses overview:

How to create and take personalised training courses online thanks to Artificial Intelligence
- 9:00-10:10 Meet the CamBioScience team to discuss hands-on and digital training courses to enhance your technical skills and advance your career.
- 10:10-10:40 How to create and take personalised training courses online thanks to Artificial Intelligence
- 10:40-12:30 Digital lecture on “CRISPR Design & Strategy” on our AI-Learning platform OBRIZUM with **Dr Oliver Baker** (King’s College London) and **Dr Ben Davies** (University of Oxford)
“Check your knowledge” interactive session!

Cerebral Organoids

Tuesday 9th October: 12:30 - 12:30

- 12:30-14:00 CamBioScience hands-on training courses overview

How to create and take personalised training courses online thanks to Artificial Intelligence
- 14:00-16:15 Digital lecture “Cerebral Organoids” on our AI-Learning platform OBRIZUM® by world leading expert in the field
Dr Madeline Lancaster (University of Cambridge)
“Check your knowledge” interactive session!

Competition Time

CamBioScience will be running a series of competitions during their training courses with some fantastic prizes. Make sure you come along to the CamBioScience Training Zone located in the Exhibition Hall to find out more!

Session Summary:

Chemistry Innovations

Tuesday 9th October 2018: Platinum Suite 1



Session Chairs: Martin Swarbrick (CRUK TDL) & Nicole Hamblin (Charles River)

The role of medicinal chemistry in small molecule drug discovery is well established and continues to deliver a strong pipeline of novel medicines for patients.

In recent years medicinal chemists have also been pushing the boundaries of their discipline, applying medicinal chemistry principles to large molecule drug design and to the field of chemical biology to deliver

novel approaches, technologies and tools to study and manipulate biological systems.

This session will feature leading industry and academic medicinal chemists describing successful delivery of clinical candidates and showcasing recent advances in novel chemical biology approaches, with application to both small and large molecule drug discovery.

Technology Spotlights sponsored by:



08:00 - 08:45

08:45 - 09:00 **Steve Rees** (ELRIG Chairman)

09:00 - 09:15 **Conference Directors**

09:15 - 10:15

REGISTRATION

ELRIG Annual Review

Conference & Plenary Keynote Introduction

PLENARY KEYNOTE:

Drug re-purposing for ageing research

Professor Janet Thornton (European Bioinformatics Institute)

10:15 - 10:50

COFFEE

10:50 - 11:00 **Session Chairs**

Introduction

11:00 - 11:30 **Gemma Mudd**
(Bicycle Therapeutics)

Highly potent and selective tumour targeting bicyclic peptides - a novel approach to cancer therapy

11:30 - 11:45 **Poster Spotlight: Thomas Christott** (SGC, University of Oxford)

How the chemical design & synthesis of linkers used in antibody drug conjugates drives the success of ADC drug development.

11:45 - 12:15 **Mark Frigerio**
(AstraZeneca)

Technology Spotlight

12:15 - 12:20 **Hugo Viana** (Merck)

Technology Spotlight

12:20 - 12:25 (Eurofins Pharma Discovery Services)

12:25 - 12:30 **Michael Palmowski** (I&L Biosystems UK Ltd) Technology Spotlight

12:30 - 14:00

LUNCH & POSTERS

14:00 - 14:30 **Bernard Barlaam**
(AstraZeneca)

Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of haematological malignancies.

14:30 - 14:45 **Poster Spotlight: Linos Lazarides** (Eurofins Pharma Discovery Services)

14:45 - 15:15 **Doru Roiban**
(GlaxoSmithKline)

Biocatalysis in Drug Discovery

15:15 - 15:20 (Malvern Panalytical Ltd)

Technology Spotlight

15:20 - 15:25 (Tecan UK Ltd)

Technology Spotlight

15:25 - 15:30 **David Bunka** (Aptamer Group Limited)

Technology Spotlight

15:30 - 16:00

COFFEE

16:00 - 16:30 **Andrew Cridland**
(Charles River)

Capture Compound® Mass Spectrometry: On- and Off-Target Deconvolution

16:30 - 17:00 **Matthew Cheeseman**
(The Institute of Cancer Research)

Using PROTACs as probes to study intracellular target engagement against proteins with unknown function

17:00 - 18:45

DRINKS RECEPTION & POSTERS

Session Summary

Innovations in cellular HTS and compound profiling

Tuesday 9th October 2018: Platinum Suite 2



Session Chairs: Eddy Stevens (Ario Pharma) & Mark Slack (Evotec)

Efforts continue to try and improve the quality and relevance of the hit identification process with the ultimate goal of decreasing late stage attrition. Increased understanding of the biochemical pathways driving disease, continue to lead to new developments at all stages of the process: from small molecule

library design through to complex biological models. Traditional target-based approaches are giving way to complex, heterogenous cellular models employing a variety of readouts combined with image based and big data set analysis. Within this session we aim to case study some of these recent developments.

Technology Spotlights sponsored by:




08:00 - 08:45	REGISTRATION	
08:45 - 09:00	Steve Rees (ELRIG Chairman)	ELRIG Annual Review
09:00 - 09:15	Conference Directors	Conference & Plenary Keynote Introduction
PLENARY KEYNOTE: PLATINUM SUITE 1		
Drug re-purposing for ageing research Professor Janet Thornton (European Bioinformatics Institute)		
09:15 - 10:15		
10:15 - 10:50	COFFEE	
10:50 - 11:00	Session Chairs	Introduction
11:00 - 11:30	Martin Guilliams (VIB institute for inflammation)	Using Single Cell Sequencing for Drug Discovery
11:30 - 11:45	Poster Spotlight:	
11:45 - 12:15	Lorena Kallal (GlaxoSmithKline)	Cellular thermal shift assays in high throughput: a 1536-well cellular target engagement assay for drug discovery
12:15 - 12:20	Michael Dabrowski (Pelago Bioscience AB)	Technology Spotlight
12:20 - 12:25	Nirmal Perera (LGC - ATCC)	Technology Spotlight
12:25 - 12:30	Sharon Barnard (INTEGRA Bioscience Ltd)	Technology Spotlight
12:30 - 14:00	LUNCH & POSTERS	
14:00 - 14:30	Steffen Jaensch (Janssen Pharmaceutica)	Efficiently identifying and characterizing HTS hits with imaging biosignatures
14:30 - 14:35	Peter Djali (Formulatrix)	Technology Spotlight
14:35 - 14:45	Poster Spotlight: Bomi Jung (AstraZeneca)	
14:45 - 15:15	Magda Bictash (ARUK)	Implementation of a patient derived disease model using human iPSC for drug screening
15:15 - 15:20	Ewan Grant (Beckman Coulter GmbH)	Technology Spotlight
15:20 - 15:25	Carsten Mang (Hamilton Sales & Service Ltd)	Technology Spotlight
15:25 - 15:30	Craig Malcolm (Promega UK Ltd)	Technology Spotlight
15:30 - 16:00	COFFEE	
16:00 - 16:30	Robert Vries (Hubrecht Organoid technology)	Organoids: Predicting clinical responses in an in vitro model
16:30 - 17:00	Cristina Bertulli (Cambridge University)	Biomicrofabrication of Cellular Interfaces and Models
17:00 - 18:45	DRINKS RECEPTION & POSTERS	

Session Summary

Anti-infectives & Rare Diseases

Tuesday 9th October 2018: Platinum Suite 3



Session Chairs: David Brown (Healx Ltd) & Chris Dowson (Warwick University)

Rare diseases and infectious diseases have been relatively neglected for funding in both the private and public sector and both often do not respond well to the single target/single drug paradigm thus requiring combination therapies for efficacy; and as a result, both have thin drug pipelines. Over the past 20 years this landscape has been transformed in advanced

economies by implementation of commercial incentives such as the Orphan Disease Act in the USA and Orphan designation in the EU, which lead to new business models and invention of much needed medicines. In this session we will explore the exciting possibilities ahead for multi-targeting in both rare diseases and infectious diseases.

Technology Spotlights sponsored by:



08:00 - 08:45		REGISTRATION
08:45 - 09:00	Steve Rees (ELRIG Chairman)	ELRIG Annual Review
09:00 - 09:15	Conference Directors	Conference & Plenary Keynote Introduction
PLENARY KEYNOTE: PLATINUM SUITE 1		
Drug re-purposing for ageing research Professor Janet Thornton (European Bioinformatics Institute)		
09:15 - 10:15		
10:15 - 10:50		COFFEE
10:50 - 11:00	Session Chairs	Introduction
11:00 - 11:30	Michale Bouskila-Chubb (Healx Ltd)	Using AI to accelerate combinations drug discovery for rare diseases
11:30 - 11:45	Poster Spotlight: Clio Andreea (Charles River Laboratories)	
11:45 - 12:15	Ursula Theuretzbacher (Center for Anti-Infective Agents)	Economic models to incentivise antibacterial drug R&D
12:15 - 12:20	(Labcyte Inc.)	Technology Spotlight
12:20 - 12:25	Louise Affleck (Cisbio)	Technology Spotlight
12:25 - 12:30	(Bio-Rad)	Technology Spotlight
12:30 - 14:00		LUNCH & POSTERS
14:00 - 14:30	Steven Zimmer (MitoDys Therapeutics)	An academic entrepreneur's thoughts about drug discovery where reductionism bumps up against biological complexity and drug promiscuity: generating meaningful targets
14:30 - 14:45	Poster Spotlight:	
14:45 - 15:15	William Hope (University of Liverpool)	The case for combination antimicrobial chemotherapy for AMR
15:15 - 15:20	David Sorrell (Horizon Discovery)	Technology Spotlight
15:20 - 15:25	Amanda J Woodrooffe (Biolvt)	Technology Spotlight
15:25 - 15:30	(LGC-ATCC)	Technology Spotlight
15:30 - 16:00		COFFEE
16:00 - 16:30	Chris Dowson (University of Warwick)	Multi-targeting to reduce bacteria resistance
16:30 - 17:00	David Brown (Healx Ltd)	Combination drugs for safe treatment of children with rare cancers
17:00 - 18:45		DRINKS RECEPTION & POSTERS

Session Summary

The opioid crisis, addiction and the search for more effective analgesics

Tuesday 9th October 2018: Platinum Suite 4

Session Chairs: Sarah Nickolls (GlaxoSmithKline) & David Kendall (Pharmnovo)



Hosted by:



**BRITISH
PHARMACOLOGICAL
SOCIETY**

Opioids have been the mainstay of pain medication for many years. They are valuable assets for treating acute pain, however their efficacy in treating chronic pain is extremely limited and their liability to cause addiction has led to an “opioid crisis” in many countries. In this session we will discuss at the reward pathways of the

brain, whether opioid pathways can be targeted more selectively to reduce their propensity for negative side effects and focus on some of the other promising mechanisms for treating chronic pain currently under investigation.

08:00 - 08:45	REGISTRATION	
08:45 - 09:00	Steve Rees (ELRIG Chairman)	ELRIG Annual Review
09:00 - 09:15	Conference Directors	Conference & Plenary Keynote Introduction
PLENARY KEYNOTE: PLATINUM SUITE 1		
Drug re-purposing for ageing research Professor Janet Thornton (European Bioinformatics Institute)		
09:15 - 10:15		
10:15 - 10:50	COFFEE	
10:50 - 11:00	Session Chairs	Introduction
11:00 - 11:30	Prof Eamonn Kelly (University of Bristol)	Ligand bias at opioid receptors - what is it good for?
11:30 - 12:00	Prof Marzia Malcangio (Kings College London)	Neuro-immune interactions and novel targets for chronic pain
12:00 - 12:30	Dr Kirstie Bennett (Heptares Therapeutics)	Targeting the reward system in addiction – structure-based drug design of selective orexin 1 receptor antagonist
12:30 - 14:00	LUNCH & POSTERS	
14:00 - 14:30	Dr Zahid Ali (Mundipharma)	Current progress and future opportunities in the development of Nav1.7 blockers for the treatment of pain
14:30 - 15:00	Dr Alex Gutteridge (GlaxoSmithKline)	Natural and engineered genetics for new pain target discovery
15:00 - 15:30	Prof Vicky Chapman (University of Nottingham)	Mechanisms based approaches to novel analgesic development: what are the alternatives to opioids for chronic pain?
15:30 - 16:00	COFFEE	
16:00 - 16:30	David Kendall (PharmNovo AB/UK)	Delta opioid receptor agonists; potential in chronic pain therapy
16:30 - 17:00	Prof Dave Finn (NUI Galway)	Altered pain processing in a rat model of negative affective state: a role for the endogenous cannabinoid and opioid systems
17:00 - 18:45	DRINKS RECEPTION & POSTERS	

Session Summary:

Innovations in biochemical and biophysical hit finding techniques

Wednesday 10th October 2018: Platinum Suite 1



Session Chairs: Geoff Holdgate (AstraZeneca) & Andrew Scott (Concept Life Sciences)

Recently we have seen a change in culture to traditional hit finding, to include alternative screening paradigms such as fragment, focussed library and iterative screening. This has been coupled with the improvement in speed and automation of several biophysical techniques directly detecting small molecule and protein interactions. In addition, increasingly more detailed mechanistic information is sought earlier in the drug discovery process and understanding

the kinetics and mode of action, as well as the traditional thermodynamic parameters, in both a biochemical and a biophysical setting is viewed as important in identifying the most promising hits leading to lead series.


This session will provide an overview and update of the developing methods that can be employed to gain this more detailed insight which ultimately allows identification of the best hits.

Technology Spotlights sponsored by:



08:00 - 09:00	REGISTRATION	
09:00 - 09:10	Steve Rees (ELRIG Chairman)	Conference & Plenary Keynote Introduction
PLENARY KEYNOTE: PLATINUM SUITE 1		
09:10 - 10:10	Opportunities in the Golden Age of Biology Dr Jonathan Milner (Meltwind)	
10:10 - 10:40	COFFEE	
10:40 - 10:50	Session Chairs	Introduction
10:50 - 11:20	James Murray (Vernalis R&D Ltd)	Crude reaction screening: KA/D, kd, structure and more
11:20 - 11:25	Chris Tomlinson (Signature Discovery)	Technology Spotlight
11:25 - 11:30	Catherine Wark (BMG Labtech Ltd)	Technology Spotlight
11:30 - 12:00	Deepika Srivastava (AstraZeneca)	Application of Acoustic Mist Ionization Mass Spectrometry (AMI-MS) for the Development of Kinase Assays
12:00 - 12:15	Poster Spotlight: Radoslaw Bombera (BioNavis Ltd)	
12:15 - 12:20	Moritz Pfreundschuh (Genedata AG)	Technology Spotlight
12:20 - 12:25	Amrit Duhela (Thermo Fisher Scientific)	Technology Spotlight
12:25 - 12:30	Anna Groom (LabLogic Systems Ltd)	Technology Spotlight
12:30 - 14:00	LUNCH	
14:00 - 14:30	Martin Redhead (UCB)	Biophysical and Biochemical assay technologies for antibody discovery, and considerations for their uses
14:30 - 15:00	Steve Anderton (Aquila BioMedical)	Immunoassays for Drug Discovery: Balancing complex cellular systems with high throughput screening.
15:00 - 15:15	Poster Spotlight: Andrew Jones (Domainex)	
15:15 - 15:45	Scott Pollack (Signature Discovery)	Smarter IDO inhibitor profiling by incorporating biophysical, biochemical and cellular target engagement approaches
15:45 - 16:15	Helena Lindmark (AstraZeneca)	Fluorescence assay technologies for hit discovery
16:15 - 16:30	CLOSE OF CONFERENCE & PRIZE DRAW - PLATINUM SUITE 1	

Session Summary:



Antibodies and Novel Large Molecule Platforms

Wednesday 10th October 2018: Platinum Suite 2

Session Chairs: David Matthews (LifeArc) & Andy Popplewell (UCB)

Antibodies and antibody-based drugs have become a highly successful therapeutic modality, due in part to the exquisite specificity and the affinity of the antibody / antigen interaction. 2017 saw a record number of regulatory approvals for therapeutic antibodies, and with many more molecules in late stage trials this trend is set to continue.

The next wave of therapeutic antibodies will include many novel modalities: from antibody drug

conjugates to multi-specific formats; from novel scaffolds to Fc-regions with enhanced effector activities. Technological advances and innovation in antibody discovery, expression, engineering and developability are all contributing to this upsurge in antibody candidate molecules. In this session we aim to cover some of these enabling technologies and latest platform innovations, as well as to consider some of the latest clinical developments for tomorrow's therapeutic antibodies.



Technology Spotlights sponsored by:



08:00 - 09:00		REGISTRATION
09:00 - 09:10	Steve Rees (ELRIG Chairman)	Conference & Plenary Keynote Introduction
09:10 - 10:10		PLENARY KEYNOTE: PLATINUM SUITE 1 Opportunities in the Golden Age of Biology Dr Jonathan Milner (Meltwind)
10:10 - 10:40		COFFEE
10:40 - 10:50	Session Chairs	Introduction
10:50 - 11:20	David Brockwell (Astbury Centre, University of Leeds)	Assessing and Addressing Biopharmaceutical Aggregation
11:20 - 11:25	Katrina Kidd (Sartorius Stedim Biotech)	Technology Spotlight
11:25 - 11:30	Leanne Wickens (Promega UK Ltd)	Technology Spotlight
11:30 - 12:00	Ahmad Kamal (UCB Celltech)	Patient-Focused Bispecific Target Discovery by High Throughput Functional Screening
12:00 - 12:30	Lotta Räty (Miltenyi Biotec Ltd)	Automation meets cell separation: primary cells for immuno oncology assays.
12:30 - 14:00		LUNCH
14:00 - 14:30	Charlotte Deane (University of Oxford)	Structurally mapping next-generation sequencing repertoires of antibodies to aid in-silico therapeutic design
14:30 - 15:00	Pawel Stocki (Ossianix Inc)	Single domain antibody platform for delivery of biologics across the blood brain barrier
15:00 - 15:15	Poster Spotlight: Aneesh Karatt Vellatt (IONTAS Ltd)	
15:15 - 15:45	Bryan Edwards (Antikor Biopharma)	Targeting Solid Tumours with Antibody Fragment Drug Conjugates
15:45 - 16:15	Stephen Ashman (GlaxoSmithKline)	The Discovery of Anti-BCMA: One Antibody, Two Flavours
16:15 - 16:30		CLOSE OF CONFERENCE & PRIZE DRAW - PLATINUM SUITE 1

Session Summary:

Drug Discovery Networks- Alliances, Partnerships, CRO Relationships & Open Innovation



Wednesday 10th October 2018: Platinum Suite 3

Session Chairs: Andy Pearce (GSK) & Julie Freadson (CRL)

Over the last decade drug discovery and development has evolved from the norm of a single organisation looking internally to achieve the entire process from target discovery through early development and launch, to a landscape where almost all drug discovery candidates emerge from one or often a series of partnerships and collaborations. This session will feature the perspectives of leading experts from across

the spectrum of disciplines and organisations involved in delivering an innovative candidate medicine through partnerships. Presentations will be business and science focussed featuring case studies and learnings to illustrate the increasing diversity of drug discovery execution paths and the key principles that underlie effective cross-sector drug discovery partnerships.

Technology Spotlights sponsored by:



08:00 - 09:00

REGISTRATION

09:00 - 09:10 **Steve Rees (ELRIG Chairman)**

Conference & Plenary Keynote Introduction

09:10 - 10:10

PLENARY KEYNOTE: PLATINUM SUITE 1
Opportunities in the Golden Age of Biology
Dr Jonathan Milner (Meltwind)

10:10 - 10:40

COFFEE

10:40 - 10:50 **Session Chairs**

Introduction

10:50 - 11:20 **Aled Edwards (M4K Pharma)**

A business model for open drug discovery

11:20 - 11:25 (LifeArc)

Technology Spotlight

11:25 - 11:30 **Richard Griesbach (NMI TT Pharmaservices)**

Technology Spotlight

11:30 - 12:00 **Graeme Wilkinson (Medicines Discovery Catapult)**

Medicines Discovery Catapult: a new model for collaborative R&D

12:00 - 12:15 **Poster Spotlight: Catherine Goh (siTOOLs Biotech)**

Technology Spotlight

12:15 - 12:20 **David Bunton (ReproCELL)**

Technology Spotlight

12:20 - 12:25 **Hardeep Grewal (Merck)**

Technology Spotlight

12:25 - 12:30 (FUJIFILM Cellular Dynamics)

Technology Spotlight

12:30 - 14:00

LUNCH

14:00 - 14:30 **Laurence Barker (Dementia Discovery Fund)**

The Dementia Discovery Fund – a novel, collaborative venture

14:30 - 15:00 **Mark Slack (Evotec)**

Building bridges: An academic-industry exercise

15:00 - 15:15 **Poster Spotlight: Steven van Helden (Pivot Park Screening Centre)**

Discovery Partnerships with Academia, integrated collaborations leading towards innovative medicines

15:15 - 15:45 **Duncan Holmes (GlaxoSmithKline)**

Apollo Therapeutics - a novel, collaborative drug discovery model

15:45 - 16:15 **Richard Butt (Apollo Therapeutics)**

CLOSE OF CONFERENCE & PRIZE DRAW - PLATINUM SUITE 1

Session Summary:

Data Sciences and Artificial Intelligence:



Wednesday 10th October 2018: Platinum Suite 4

Session Chairs: John Overington (MDC) & Bissan Al-Lazikani (The Institute of Cancer Research)

Artificial Intelligence, Big Data and High-performance computing are areas of intense interest in the drug discovery and development sector at the current time, due to their potential impact of cost, speed and efficiency. It is clear that built on top of appropriate data, AI systems can outperform humans on certain tasks, and spot patterns and relationships within data previously out of reach. However, due to the potential of

unintended consequences in the analysis of in particular clinical data sets, AI also poses important ethical challenges. Arguably, some of the most significant real-world examples of advances in AI have been in the area of medicinal and synthetic chemistry, and in target discovery and computational validation. The session will bring together experts in the application of AI to drug discovery.

Technology Spotlight sponsored by:



08:00 - 09:00

REGISTRATION

09:00 - 09:10 **Steve Rees** (ELRIG Chairman)

Conference & Plenary Keynote Introduction

09:10 - 10:10

PLENARY KEYNOTE: PLATINUM SUITE 1

Opportunities in the Golden Age of Biology
Dr Jonathan Milner (Meltwind)

10:10 - 10:40

COFFEE

10:40 - 10:50 **Session Chairs**

Introduction

10:50 - 11:20 **Marwin Segler**
(Benevolent AI)

Computer-Aided Synthesis Planning

11:20 - 11:25 **Alan Fletcher** (PerkinElmer)

Technology Spotlight

11:25 - 11:30

Technology Spotlight

11:30 - 12:00 **Andrew Hopkins**
(ExScientia)

The Centaur Chemist: AI in drug design

POSTER SPOTLIGHT

12:15 - 12:20

Technology Spotlight

12:20 - 12:25

Technology Spotlight

12:25 - 12:30

Technology Spotlight

12:30 - 14:00

LUNCH

14:00 - 14:30 **Bissan Al-Lazikani**

Integrative Big Data for cancer therapy and drug discovery

(The Institute of Cancer Research)

POSTER SPOTLIGHT

14:30 - 15:00 **Graham Simpson**
(GTN)

Next-Generation Drug Discovery: Quantum Physics Meets Machine Learning

(GTN)

POSTER SPOTLIGHT

15:15 - 15:45 **Ola Engkvist**
(AstraZeneca)

Artificial Intelligence in Drug Discovery from a Medicinal Chemistry Viewpoint


(AstraZeneca)

15:45 - 16:15 **Matt Tudor**
(Merck)

Learning the biology of chemistry

(Merck)

CLOSE OF CONFERENCE & PRIZE DRAW - PLATINUM SUITE 1



Genome Engineering in Drug Discovery 2019: From Targets to Therapeutics

King's Centre, Oxford


27 - 28 February 2019

The inaugural ELRIG Genome Engineering in Drug Discovery: From Targets to Therapeutics meeting will be held at the King's Centre, Oxford 27 & 28 February 2019. Genome Engineering, including Zinc-finger, TALEN and most recently CRISPR/Cas9, has become a powerful tool in the drug discovery pipeline. This meeting will focus on the application of genome engineering to identify novel drug targets through large scale CRISPR based functional genomics studies, target validation in developing advanced cellular and *in vivo* disease models, and the pioneering applications in therapeutic genome editing. A current perspective of the applications of these rapidly developing technologies with a focus on drug discovery applications will be the meeting's focus.

We aim to bring together the research community working in the field of genome engineering with interests in developing and applying the technology for pharmaceutical research. Join scientists from academia, pharma, biotech, and CROs to hear talks given by speakers at the cutting edge of genome engineering, take part in commercial vendor lab-based workshops, network at the exhibition, innovation forum and speakers dinner and gain strategic insights into solutions for increasing the success of drug discovery and development.

The scientific program for this Genome Engineering in Drug Discovery meeting will include:

- Large-scale CRISPR functional genomics studies for drug target identification and validation
- Application of genome engineering in developing biological models of disease from single cell through to complex *in vitro* tissue systems and *in vivo* models
- Cutting edge CRISPR genome engineering technologies and their emerging applications
- A perspective from technology leaders toward the future therapeutic applications of genome engineering



Research & Innovation 2019 Innovations to drive future drug discovery

Homerton College, Cambridge

2 - 3 April 2019

New biology continues to emerge at a fast pace and is revealing many new and exciting therapeutic opportunities for drug discovery scientists; potential novel drug targets and new mechanisms-of-action. It is critical that the drug discovery field continually adapts and equips with new technologies and innovations that will enable targets to be prosecuted no matter which direction the cutting-edge biology has taken. Hence the 2019 ELRIG R&I conference will discuss how the most promising new biology is being identified and discovered and seek to explore what promising new technologies and innovations are emerging to enable this science to be effectively translated into successful therapeutics. The four scientific sessions will therefore address different aspects of translating new biology into drug discovery projects.

• **Innovating the future of rational drug design**

This session will explore the potential of developments in rational drug design combined with the power of algorithmic computing to increase the future pace and success of early discovery.

• **Where are new drug target hypotheses coming from?**


This session will look at how human data, new technologies and new approaches to academia-industry collaboration are combining to build a pipeline of new targets for drug discovery.

• **Therapeutic approaches of the future**

This session will survey progress in developing alternative modalities as the therapeutic approaches of the future.

• **Next generation *in vitro* models for drug efficacy & safety**

This session will address how developments such as iPS-derived cells, 3D cell culture and gene editing are also driving more predictive toxicology models and investigates technologies/innovations will drive the next generation disease models in pre-clinical drug discovery.



Advances in Cell-Based Screening 2019

AstraZeneca, Gothenburg


22 - 23 May 2019

This interactive 2-day event will host leading scientists from academia and industry to discuss current and future formats for cell based assays. In 2019, the bi-annual meeting will be accompanied by a satellite meeting on Chemical Biology on May 24th, organized by key academic infrastructures in the Nordic countries. Our aim is to create an open and inspiring environment for networking between biologists and chemists, working towards a common view on expectations from our cell assays and their use for target identification, target validation and compound profiling purposes.

Cell based assays are utilized at all stages of drug discovery to explore disease mechanisms and to identify novel molecular therapeutics. Significant advancements are being made towards cell reagents and formats that provide a more accurate biological context, aiming at improving translation to human physiology/pathophysiology. Their implementation is much needed for improving success rates in drug discovery, but there are significant challenges associated with reliable and affordable reagent supply and validation of improved translational power to justify costs. This meeting serves to explore recent advancements and to discuss their practical implementation in drug and chemical probe discovery and validation. The scientific program is developed around four key focus areas:

- **Precision Medicine in miniaturized format**
- **Phenotypic screening through advances in Precise Genome Editing**
- **Multiplexed Screening with Single Cell Resolution**
- **Target Engagement and Coherence with Functional Cellular Responses**

There will be numerous opportunities to network with scientists and researchers from the pharmaceutical, academic and vendor communities throughout the 2+1 day conference. The program also includes a poster display, including the opportunity to present in a poster spotlight and tours to the Advanced Cell lab facility at AstraZeneca.



Discovery Technologies 2019 Emerging technologies & applications in early safety assessment

Alderley Park, Cheshire

26 September 2019

Following the success of our inaugural meeting in 2018, ELRIG is pleased to invite you to the 2nd Discovery Technologies meeting to be held at Alderley Park, Macclesfield, UK on September 26th, 2019. This ELRIG meeting, which will be run in collaboration with Alderley Park, will focus on novel and emerging technologies that are improving the efficiency and success rates in the drug discovery process. The two main themes of the conference will be the application of imaging techniques in drug discovery and approaches and technologies used to address early safety assessment within the pharmaceutical industry. For 2019 the conference will include two parallel sessions:

- **Imaging Techniques in Drug Discovery**

This session will focus on the application of imaging techniques in drug discovery, including in vitro 3D imaging approaches, MS imaging and in vivo imaging applications. The use of imaging in drug discovery is becoming increasingly routine to inform decisions with applications ranging from high throughput screening to clinical assessment. This session will explore the use of imaging in fields including investigating disease specific pathophysiology's, characterising the pharmacokinetics / pharmacodynamics of molecules and defining disease specific therapeutic endpoints.

- **Approaches and technologies to address early safety assessment**

Failure rates in drug development due to adverse safety profiles are still a major problem in the industry. As a result, the pharmaceutical industry is increasingly focused on the characterisation of the safety profile in early discovery to de-risk and optimise compounds prior to further development. This session will look at approaches used to assess target organ toxicity in a discovery setting focusing on areas such as drug induced liver injury (DILI), cardiac safety assessment and immunosafety profiling of large molecules. Technology advances in this field, such as in iPSC derived and organ-on-a-chip models, will be discussed.



Drug Discovery 2019: Looking Back to the Future

ACC, Liverpool
5 - 6 November 2019


Now in its 13th year, ELRIG's flagship conference Drug Discovery 2019 will take place at ACC, Liverpool. This year's focus, 'A Look Back to the Future' is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery.

Our scientific programme will feature over 40 world-class speakers with 6 main session tracks covering the following key areas:

- Big Data and Artificial Intelligence
- Molecular and Cellular Imaging
- Models of Disease
- Hit Finding Strategies
- Chemical Biology
- Biomarkers

In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.

Drug Discovery has become the largest meeting of life sciences industry professionals in the UK. This 2-day event will bring together more than 1200 delegates and over 100 exhibiting companies from around the world who will highlight the latest ground-breaking research, discuss cutting-edge advances in the application of laboratory technology to understand disease biology and to identify novel chemical and biological candidate drugs.



ELRIG Networking Events 2019

Locations across the UK
Throughout 2019

Since the launch of ELRIG networking events at the end of 2016, there have been a series of successful meetings at various locations around the country.

These are short, usually evening sessions, encouraging collaboration between local scientists from academia, pharma and biotech and the technology industry. The focus is on developing solutions for unmet scientific or technical challenges and to create opportunities through this enhanced collaboration to engage in a beneficial manner in a localised environment.

Each event has a different theme, and involves 2-3 informal presentations by invited speakers whose work is relevant to the theme of the meeting. This is followed by a free to attend, food and drinks reception to facilitate further networking.

ELRIG will host six networking events during 2019. Planned locations are Cambridge, Cheshire, London, Nottingham, Oxford and Scotland.

We are also pleased to offer the opportunity to purchase one of a limited number of a table top exhibition spaces at one of these events. If you would like more information, please contact a member of the ELRIG team at info@elrig.org. Follow us on Twitter @**ELRIG_UK** for updates.

Drug Discovery 2018 Platinum Sponsor



Miltenyi Biotec GmbH
www.miltenyibiotec.com

Drug Discovery 2018 Gold Sponsors



Beckman Coulter GmbH
www.beckman.com



BMG LABTECH Ltd
www.bmglabtech.com



Hamilton Sales and Service UK Ltd
www.hamiltoncompany.com



INTEGRA Bioscience Ltd
www.integra-biosciences.com



KBiosystems
www.kbiosystems.com



Labcyte Inc.
www.labcyte.com



LifeArc
www.lifearc.org



Merck
www.merckmillipore.com



Sartorius Stedim Biotech
www.tapbiosystems.com



Synthevo
www.synthevo.com



Tecan UK Ltd
www.tecan.com

Drug Discovery 2018 Silver Sponsors



BioIVT
www.bioivt.com



Bio-Rad
www.bio-rad.com




Collaborative Drug Discovery
www.collaborativedrug.com/cdd-vault



Drug Discovery 2018 Bronze Sponsors

Aptamer Group Limited www.aptamergroup.co.uk	The logo for aptamer group features a blue hexagonal icon with a white 'A' inside, followed by the text 'aptamer group'.	Horizon Discovery www.horizontdiscovery.com	The logo for horizon features the word 'horizon' in a blue, sans-serif font with a blue underline.	PerkinElmer www.perkinelmer.com/lifesciences	The logo for PerkinElmer features a blue 'P' inside a blue square followed by the text 'PerkinElmer' and 'For Life Science'.
Cambridge Bioscience www.bioscience.co.uk	The logo for Cambridge Bioscience features a green hexagonal icon with a white 'C' inside, followed by the text 'cambridge bioscience'.	I&L Biosystems UK Ltd www.il-biosystems.com/de-en/	The logo for IL Biosystems features a grid of colored squares with the letters 'IL' in the center, followed by the text 'Biosystems'.	Promega UK Ltd www.promega.com	The logo for Promega features a yellow square with a black 'P' inside.
Cisbio www.cisbio.com	The logo for Cisbio features the word 'cisbio' in a blue, stylized font with a green underline, and the tagline 'ASSAYS INTERACTION IS EVERYTHING' below it.	LabLogic Systems Limited www.lablogic.com	The logo for LabLogic features the word 'LabLogic' in a blue, sans-serif font with a blue underline.	ReproCELL www.reinnervate.com	The logo for REPROCELL features a blue 'R' inside a blue circle followed by the text 'REPROCELL' and 'INTEGRATED TOOLS FOR TRANSLATIONAL RESEARCH'.
Eurofins Pharma Discovery Services www.EurofinsDiscoveryServices.com	The logo for Eurofins features the word 'eurofins' in a blue, stylized font with a blue underline, and the tagline 'Pharma Discovery Services' below it.	LGC - ATCC www.lgcstandards-atcc.org/	The logo for ATCC features the letters 'ATCC' in a blue, serif font with a blue underline.	Sygnature Discovery www.sygnaturediscovery.com	The logo for Sygnature Discovery features the words 'SYGNATURE DISCOVERY' in a blue, stylized font with a blue underline.
Formulatrix, Inc. www.formulatrix.com	The logo for Formulatrix features the word 'FORMULATRIX' in a blue, stylized font with a blue underline.	Malvern Panalytical Ltd www.malvernpanalytical.com	The logo for Malvern Panalytical features the words 'Malvern Panalytical' in a blue, stylized font with a blue underline.	Thermo Fisher Scientific www.thermoscientific.com	The logo for Thermo Fisher Scientific features the words 'Thermo Fisher SCIENTIFIC' in a red, stylized font with a red underline.
FUJIFILM Cellular Dynamics www.fujifilmcdi.com	The logo for FUJIFILM Cellular Dynamics features a green hexagonal icon with a white 'C' inside, followed by the text 'Cellular Dynamics International' and 'FUJIFILM'.	NMI TT Pharmaservices www.nmi-tt.de/pharmaservices	The logo for NMI TT Pharmaservices features the letters 'NMI TT' in a blue, sans-serif font with a blue underline.		
Genedata AG www.genedata.com/screener	The logo for Genedata features the word 'Genedata' in a blue, stylized font with a blue underline, and the tagline 'solutions in silico' below it.	Pelago Bioscience AB www.pelagobio.com	The logo for Pelago Bioscience features the word 'PELAGO' in a blue, stylized font with a blue underline.		

Drug Discovery 2018 Exhibitors

Admescope Ltd www.admescope.com		Charles River www.criver.com		Proteintech Europe www.ptglab.com	
Agilent Technologies www.agilent.com		CytoSMART Technologies BV www.cytosmart.com		Proteome Sciences Plc www.proteomics.com	
Andrew Alliance www.andrewalliance.com		ELRIG UK www.elrig.org		Reaction Biology Corporation www.reactionbiology.com	
Apollo Scientific www.apolloscientific.co.uk		European Collection of Authenticated Cell Cultures www.phe-culturecollections.org.uk		Sarstedt Ltd www.sarstedt.com	
Aurelia Bioscience www.aureliabio.com		Fritz Gyger AG www.fgyger.ch		SB Drug Discovery www.sbdrugdiscovery.com	
Bineat www.bineat.co.uk		Greiner Bio One www.gbo.com		STEMCELL Technologies www.stemcell.com	
BioAscent Discovery Ltd www.bioascent.com		Idea Bio-Medical Ltd www.idea-bio.com		Taconic www.taconic.com	
BioNavis Ltd www.bionavis.com		Medicines Discovery Catapult www.md.catapult.org.uk		Takara Bio Europe www.takarabio.com	
Biosero, Inc www.biosero.com		Metrion Biosciences Limited www.metrionbiosciences.com		Tissue Solutions www.tissue-solutions.com	
BioTek Instruments Ltd www.bioteck.com		MIP Diagnostics Limited www.mip-dx.com		Titian Software Ltd www.titian.co.uk	
BlueCatBio GmbH www.bluecatbio.com		Molecular Devices (UK) Ltd www.moleculardevices.com		UPM-Kymmene Corporation www.growdex.com	
Brooks Life Science www.brookslifesciences.com		Peak Analysis Automation Ltd www.paa-automation.com		Wagner Medizin- und Pharmatechnik GmbH & Co. KG www.medizin-pharmatechnik.de	
Cambridge Research Biochemicals www.crbdiscovery.com		Peak Proteins Ltd www.peakproteins.com		Ziath www.ziath.com	
Cancer Research www.discoverylabs.cancerresearchuk.org		Porvair Sciences Ltd www.porvair-sciences.com			

Drug Discovery 2018 Innovation Zone

Axion Biosystems www.axionbiosystems.com		Life Science Methods B.V. www.lifesciencemethods.com		ScreenIn3D www.screenin3d.com	
BioSystems Technology www.biosystemstechnology.com		MicroMatrices Associates Ltd www.micromatrices.com		Xpert Automation www.xpert-automation.com/en	
Cell Guidance Systems www.cellgs.com		Newcells Biotech www.newcellsbiotech.co.uk			
Ectica Technologies AG www.ectica-technologies.com		Phasefocus www.phasefocus.com			

Drug Discovery 2018 Career & Media Partners

BioHub www.biocity.co.uk/ biohub-alderley-park		Drug Target Review www.drugtargetreview.com		Technology Networks www.technologynetworks.com	
Biostrata www.biostratamarketing.com		European Biopharmaceutical Review www.samedanltd.com/magazine/12		UKSPA www.scienceparks.co.uk	
British Pharmacological Society www.bps.ac.uk		GEN www.genengnews.com		UK Pharmacogenetics & Stratified Medicine Network www.uk-pgx-stratmed.co.uk	
Drug Discovery News www.ddn-news.com		Langton Howarth www.langtonhowarth.co.uk		Zyme Communications www.zymecommunications.com	
Drug Discovery Today www.drugdiscoverytoday.com		RxNet www.medchemnet.com			
Drug Discovery World www.ddw-online.com		Select Science www.selectscience.net			